References
- Doerrenberg M, Kloetgen A, Hezaveh K, Wössmann W, Bleckmann K, Stanulla M, et al. T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. Genes Chromosomes Cancer 2017;56:159-67.
- Durinck K, Goossens S, Peirs S, Wallaert A, van Loocke W, Matthijssens F, et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol 2015;43:625-39.
- Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541-52.
- Qian M, Zhao X, Devidas M, Yang W, Gocho Y, Smith C, et al. Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children. J Natl Cancer Inst 2019;111:1350-7.
- Mansur MB, van Delft FW, Colman SM, Furness CL, Gibson J, Emerenciano M, et al. Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia. Br J Haematol 2015;171:574-84.
- Gustafsson BM, Mattsson K, Bogdanovic G, Leijonhufvud G, Honkaniemi E, Ramme K, et al. Origins ofSTIL-TAL1fusion genes in children who later developed paediatric T-cell acute lymphoblastic leukaemia: An investigation of neonatal blood spots. Pediatr Blood Cancer 2018;65:e27310.
- Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, de Lorenzo P, et al. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment. Leukemia 2010;24:903-7.
- van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, de Lorenzo P, et al. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. Haematologica 2016;101:e95-8.
- Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119:34-43.
- Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: Results from an international phase III randomized study. J Clin Oncol 2019;37:2246-56.
- van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 2015;125:13-21.
- Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016;2016:580-8.
- Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, et al. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest 2020;130:863-76.
- Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ, et al. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia. Mol Cancer 2010;9:284.
- Pieters R, Schrappe M, de Lorenzo P, Hann I, de Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 2007;370:240-50.
- Pennella CL, Deu MA, Rossi JG, Baialardo EM, Alonso CN, Rubio P, et al. No benefit of Interfant protocols compared to BFM-based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina. Pediatr Blood Cancer 2020;67:e28624.
- Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: Results from the children’s oncology group AALL0434 methotrexate randomization. J Clin Oncol 2018;36:2926-34.
- Teachey DT, O’Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 2020;135:159-66.
- McMahon CM, Luger SM. Relapsed T cell ALL: Current approaches and new directions. Curr Hematol Malig Rep 2019;14:83-93.
- Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, et al. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol 2017;179:272-83.
- Hartz B, Löbel U, Hagel C, Escherich G. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am J Hematol 2013;88:1096-7.
- Jabeen K, Ashraf MS, Iftikhar S, Belgaumi AF. The impact of socioeconomic factors on the outcome of childhood acute lymphoblastic leukemia (ALL) treatment in a low/middle income country (LMIC). J Pediatr Hematol Oncol 2016;38:587-96.
- Khokhar MA, Ali MM, Liaqat S, Moin A, Sarwar HA, Sarwar MZ. A review of access to cancer facilities in Punjab, Pakistan. Cancer Rep 2020;3:e1245.
- Jabbar N, Mansoor N, Nadeem K, Maqsood S, Butt Z, Ashraf S. Prednisolone prophase for a week versus upfront multiagent chemotherapy in childhood acute lymphoblastic leukemia: An analysis with reference to induction mortality in a developing country. J Pediatr Hematol Oncol 2020;42:181-4.